Foundayo (Orforglipron) Dosing Instructions
Start Foundayo at 0.8 mg once daily, then escalate the dose every 30 days (0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg maximum) based on tolerability and weight loss response. 1
Administration Details
How to Take:
- Take once daily, with or without food 1
- Swallow tablets whole — do not break, crush, or chew 1
- Never take more than one tablet per day 1
Dose Escalation Schedule
The titration follows a structured monthly progression 1:
- Week 0-4: 0.8 mg once daily (starting dose)
- Week 4-8: 2.5 mg once daily (after at least 30 days)
- Week 8-12: 5.5 mg once daily (after at least 30 days on 2.5 mg)
- Week 12+: May increase to 9 mg, then 14.5 mg, then 17.2 mg once daily
- Each increase requires at least 30 days on current dose
- Base escalation on treatment response and tolerability
- Maximum dose: 17.2 mg once daily 1
Important Dose Modifications
With Strong CYP3A4 Inhibitors:
- Maximum dose is 9 mg once daily when used with strong CYP3A4 inhibitors 1
- Avoid concomitant use with drugs that are both strong CYP3A4 inhibitors AND OATP1B inhibitors 1
Clinical Context
Foundayo is indicated for weight management in combination with reduced-calorie diet and increased physical activity in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity 1. In clinical trials, the 17.2 mg dose achieved mean weight reductions of 11-14% at 72 weeks, with 54.6% of patients achieving ≥10% weight loss 1, 2. The medication demonstrated consistent cardiometabolic benefits including improvements in blood pressure, triglycerides, and waist circumference 3, 2.
Key Safety Considerations
Most Common Side Effects (≥5%): Nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, GERD, flatulence, and hair loss 1. These are typically mild-to-moderate and occur primarily during dose escalation 4, 2.
Contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 1
- Known serious hypersensitivity to orforglipron 1
Warnings: Monitor for acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from volume depletion, hypoglycemia (especially with insulin/secretagogues), hypersensitivity reactions, gallbladder disease, and pulmonary aspiration risk during anesthesia 1. Patients with diabetic retinopathy should be monitored for progression 1.
Planned Surgeries: Instruct patients to inform healthcare providers of any planned surgeries or procedures due to aspiration risk with GLP-1 receptor agonists 1.